World Heart Federation Cholesterol Roadmap 2022
Year: 2022
Type: review
Abstract: Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD. The present update of the World Heart Federation Cholesterol Roadmap provides a conceptual framework for the development of national policies and health systems approaches, so that potential roadblocks to cholesterol management and thus ASCVD prevention can be overcome. Methods: Through a review of published guidelines and research papers since 2017, and consultation with a committee composed of experts in clinical management of dyslipidaemias and health systems research in low-and-middle income countries (LMICs), this Roadmap identifies (1) key principles to effective ASCVD prevention (2) gaps in implementation of these interventions (knowledge-practice gaps); (3) health system roadblocks to treatment of elevated cholesterol in LMICs; and (4) potential strategies for overcoming these. Results: Reducing the future burden of ASCVD will require diverse approaches throughout the life-course. These include: a greater focus on primordial prevention; availability of affordable cholesterol testing; availability of universal cholesterol screening for inherited dyslipidaemias; risk stratification moving beyond 10-year risk to look at lifetime risk with adequate risk estimators; wider availability of affordable cholesterol-lowering therapies which should include statins as essential medications globally; use of adequate doses of potent statin regimens; and combination therapies with ezetimibe or other therapies in order to attain and maintain robust reductions in LDL-C in those at highest risk. Continuing efforts are needed on health literacy for both the public and healthcare providers, utilising multi-disciplinary teams in healthcare and applications that quantify both ASCVD risk and benefits of treatment as well as increased adherence to therapies. Conclusions: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD.
Source: Global Heart
DOI: 10.5334/gh.1154
Authors: Kausik K. Ray, Brian A. Ference, Tania Séverin, Dirk Blom, Stephen J. Nicholls, Mariko H. Shiba, Wael Almahmeed, Rodrigo Alonso, Magdalena Daccord, Marat Ezhov, Rosa Fernández Olmo, Piotr Jankowski, Fernando Lanas, Roopa Mehta, Raman Puri, Nathan D. Wong, David Wood, Dong Zhao, Samuel S. Gidding, Salim S. Virani, Donald Lloyd-Jones, Fausto Pinto, Pablo Perel, Raul D. Santos
Institutions: Imperial College London, University of Cambridge, British Heart Foundation, World Heart Federation, University of Cape Town, Monash University, Osaka Medical and Pharmaceutical University, Cleveland Clinic Abu Dhabi, National Medical Research Center of Cardiology, Complejo Hospitalario de Jaén, Universidad de La Frontera, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of California, Irvine, Ollscoil na Gaillimhe – University of Galway, Capital Medical University, Beijing Anzhen Hospital, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Northwestern University, University of Lisbon, London School of Hygiene & Tropical Medicine, Universidade de São Paulo, Hospital Israelita Albert Einstein, Instituto do Coração - HCFMUSP
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: atherosclerotic cardiovascular disease, cholesterol management, apolipoprotein B, LDL cholesterol, dyslipidemia, statins, ezetimibe, lifetime cardiovascular risk, primordial prevention, health system barriers, low- and middle-income countries, health policy, medication adherence, health literacy
Open Access status: gold
Estimated APC paid: $3,300
Funders: Amgen, World Heart Federation
OpenAlex ID: W4306255617
